Result of AGM

RNS Number : 1528N

Oxford Biomedica PLC

27 May 2022

 

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 27 May 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company") , a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2022 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2022 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (25 May 2022) there were 96,063,479 ordinary shares of 50 pence each in issue, each carrying one vote per share.

	Resolution	Votes For (incl. votes at the Chairman's discretion)	Votes at other proxy Discretion	Votes Against	Votes Withheld*	Total votes cast	Result
	Ordinary resolutions
1	To receive the Company's  Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021.	71,533,247 (99.99%)	0	3,804 (0.01%)	907,786	71,537,051	Passed
2	To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2021.	57,808,878 (80.73%)	0	13,801,220 (19.27%)	834,739	71,610,098	Passed
3	To appoint Dr. Michael Hayden as a Director.	62,539,719 (87.06%)	0	9,295,954 (12.94%)	609,164	71,835,673	Passed
4	To appoint Catherine Moukheibir as a Director.	71,748,494 (99.88%)	0	86,921 (0.12%)	609,422	71,835,415	Passed
5	To appoint Namrata P. Patel as a Director.	71,746,512 (99.88%)	0	88,903 (0.12%)	609,422	71,835,415	Passed
6	To reappoint Dr. Roch Doliveux as a Director.	68,788,280 (96.81%)	0	2,264,491 (3.19%)	1,392,066	71,052,771	Passed
7	To reappoint Professor Dame Kay Davies as a Director.	69,259,453 (96.41%)	0	2,575,962 (3.59%)	609,422	71,835,415	Passed
8	To reappoint Dr. Siyamak Rasty as a Director.	71,719,604 (99.84%)	0	116,069 (0.16%)	609,164	71,835,673	Passed
9	To reappoint Stuart Paynter as a Director.	71,206,012 (99.12%)	0	629,661 (0.88%)	609,164	71,835,673	Passed
10	To reappoint Stuart Henderson as a Director.	67,003,486 (93.27%)	0	4,832,187 (6.73%)	609,164	71,835,673	Passed
11	To reappoint Dr. Heather Preston as a Director	64,708,975 (90.08%)	0	7,126,698 (9.92%)	609,164	71,835,673	Passed
12	To reappoint Robert Ghenchev as a Director.	71,526,110 (99.57%)	0	309,305 (0.43%)	609,422	71,835,415	Passed
13	To reappoint KMPG LLP as auditor.	71,831,890 (99.99%)	0	7,494 (0.01%)	605,453	71,839,384	Passed
14	To authorise the Directors to agree the remuneration of the auditor.	71,832,849 (99.99%)	0	6,921 (0.01%)	605,067	71,839,770	Passed
15	To authorise the Directors to allot shares.	67,355,882 (93.77%)	0	4,471,767 (6.23%)	617,188	71,827,649	Passed
	Special resolutions
16	To authorise the Directors to disapply pre-emption rights.	70,888,310 (98.70%)	0	937,061 (1.30%)	619,466	71,825,371	Passed
17	To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments.	70,922,796 (98.74%)	0	903,407 (1.26%)	618,634	71,826,203	Passed
18	To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.	69,350,429 (96.53%)	0	2,489,321 (3.47%)	605,087	71,839,750	Passed

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

In addition, further to the announcements by the Company in January and April, John Dawson has stepped down from the Company's Board of Directors after more than thirteen years of service with effect from the conclusion of today's AGM.

-Ends-

Enquiries:  Oxford Biomedica plc: T: [phone] / E: [e-mail]

Stuart Paynter, Chief Financial Officer Sophia Bolhassan, Head of Investor Relations

Consilium Strategic Communications: T: [phone] / E: [e-mail] Mary-Jane Elliott / Matthew Neal / Matthew Cole

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

 

END

 

 

RAGSEUFMWEESEII